For the first time, our study demonstrates that dual-target CAR T-cell therapy (CD19/20) achieves a superior therapeutic compared to single-target CAR T-cell therapy (CD19) in the treatment of R/R DLBCL, significantly extending median survival. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.